Centessa Pharmaceuticals PLC ADR
Stock Chart, Company Information, and Scan Results
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Centessa Pharmaceuticals PLC ADR Company Information, Fundamentals, and Technical Indicators
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Centessa Pharmaceuticals PLC ADR In Our Stock Scanner
As of Jun 12, 2026Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.